Bayer stepped up its Consumer Health innovation efforts in 2020 in line with its turnaround plan for the business, and now has more than 100 projects in development.
Bayer Consumer Health ramped up its R&D activities in 2020 in line with business head Heiko Schipper’s plan to address a historically low level of innovation.
Join thousands of industry professionals who rely on HBW Insight for daily insights
Already a subscriber?
Just under half of Austrian pharmacists surveyed by Elpato Medien are “convinced that the OTC business will ensure the survival of their pharmacy.”
The US Food and Drug Administration has released a roadmap to adopt new approach methodologies in lieu of animal testing for monoclonal antibody therapies and other drugs, which may include OTC drugs though the proposal does not specifically include cosmetics.
An application for melatonin as an OTC medicine is on the agenda for the next German switch committee meeting, despite the hormone being widely available in food supplements. Acyclovir as a buccal tablet and second-generation antihistamine rupatadine are also up for discussion.
